RxDoctor Payments DataLook up a doctor →

Roman Politi, MD

Neurology · Marquette, MINPI 1588656466

Payments from drug & device makers

$200,828in general payments, 2019–2025

Across 909 payments — averaging $220.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acorda Therapeutics, Inc$77K
  • AbbVie$51K
  • Acadia Pharmaceuticals Inc$24K
  • Sanofi$14K
  • Biohaven Pharmaceuticals, Inc.$11K
  • Livanova USA, Inc.$6K
  • plus $19K from 48 others

What the payments were for

  • Consulting fees$9,4505%
  • Speaking & faculty fees$141,81871%
  • Travel & lodging$28,90214%
  • Food & beverage$20,21210%
  • Education$4450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$200,828 in reported general payments places this provider in the 90th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$163,374
Medicare patients
224
Services billed
15,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EvrysdiRisdiplam17$446,784
TecfideraDimethyl Fumarate16$201,493
NuplazidPimavanserin Tartrate36$197,009
QuliptaAtogepant67$83,532
Nurtec OdtRimegepant Sulfate57$54,219
GlatopaGlatiramer Acetate15$51,748
BriviactBrivaracetam33$51,274
UbrelvyUbrogepant46$48,706
AptiomEslicarbazepine Acetate22$39,039
Emgality PenGalcanezumab-Gnlm52$38,594
RytaryCarbidopa/Levodopa17$32,816
Dalfampridine ErDalfampridine29$25,554
Teriflunomide32$21,908
Aimovig AutoinjectorErenumab-Aooe18$19,019
Ajovy AutoinjectorFremanezumab-Vfrm22$17,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Evrysdi$129$446,78417 claims
BiogenTecfidera$786$201,49316 claims
Acadia Pharmaceuticals IncNuplazid$23,801$197,00936 claims
AbbVieQulipta, Ubrelvy$50,509$132,238113 claims
PfizerNurtec Odt$173$54,21957 claims
UCB, Inc.Briviact$254$51,27433 claims
Sunovion Pharmaceuticals Inc.Aptiom$24$39,03922 claims
Amneal Pharmaceuticals LLCRytary$334$32,81617 claims
SK Life Science, Inc.Xcopri$63$13,62712 claims
Neurelis, Inc.Valtoco$332$11,61915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 652 neurology providers in Michigan.

Other neurology in Marquette

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →